Remove Capital Raising Remove IPO Remove Portfolio
article thumbnail

How Merchant Banks Help Businesses Grow and Succeed

Razorpay

Portfolio Management Merchant banking companies provide portfolio management services to high -net-worth individuals and corporate investors. These services include a selection of securities, portfolio monitoring and review, advice on the rationalization of portfolios, and tax planning.

Bank 52
article thumbnail

M&A Heats Up in the Bakery Market

Focus Investment Banking

Many smaller operators who are well positioned with a solid customer base, a robust portfolio of goods, and healthier product lines could explore a sale at today’s attractive pricing, with options to sell to an industry competitor or a private equity group (PEG). Bakery industry challenges remain, and the market is increasingly competitive.

M&A 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Event-Driven Hedge Funds: The Best Home for Bankers Turned Investors?

Mergers and Inquisitions

Special Situations – These funds focus on companies that are spinning off or divesting divisions, reorganizing, or otherwise going through more unusual changes (not just simple acquisitions or capital raises). 5) Portfolio Concentration – Many special situations and distressed funds run concentrated portfolios (e.g.,

Funds 64
article thumbnail

24 venture capital firms you need to know about – Growth Business guide

Growth Business

By Rory Bennett on Growth Business - Your gateway to entrepreneurial success On the face of it, Britain’s venture capital firms have never been more ready to invest in your start-up. Last year, venture capital raised £6.8 Capital invested by venture capital trusts increased by 8 per cent last year to £664 million.

Capital 52
article thumbnail

Biotech Hedge Funds: A Match Made in Heaven

Mergers and Inquisitions

In technology, as a startup keeps raising capital, it normally does so at gradually higher valuations as its customers, users, and revenue grow. But in biotech, companies valuations often remain close to their total capital raised until much later in the process (i.e.,

Funds 64